An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

Clinical trial NCT07161700 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT07161700
Sponsor: Seaport Therapeutics
Status: ENROLLING_BY_INVITATION
Phase: Phase 2
Study type: INTERVENTIONAL

Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress

Start date: 2025-09-02
Primary completion: 2027-05-01
Enrollment: 360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.